With an aim to combat the challenges of epilepsy, Thane-based pharma firm Akumentis Healthcare, owned by Akums Drugs and Pharmaceuticals, has launched Clasepi.
Clasepi, DCGI-approved prescription cannabidiol (CBD) is specifically formulated to address seizures linked with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older.
Clasepi marks a development as the first synthetic CBD product of its kind to be made available in India. The product with Tetrahydrocannabinol (THC) content below 0.1%, stands out for its non-psychotropic nature. Clinical studies have demonstrated Clasepi efficacy in reducing seizures, especially in cases where conventional antiseizure medications have proven ineffective.
According to the World Health Organisation (WHO), epilepsy constitutes a considerable portion of the global disease burden, affecting approximately 50 million people worldwide, with 20% of patients residing in India. WHO asserts that up to 70% of individuals with epilepsy could achieve seizure freedom with the proper use of progressive anti seizure medicines.
